MM 是一种常见的癌症，不幸的是，每年都会导致大量死亡。大多数报告的多发性骨髓瘤病例都是在晚期才发现的，这给治疗带来了巨大的挑战。此外，所有 MM 患者最终都会产生耐药性或出现复发；因此，需要在治疗方面取得进展。然而，开发新的抗癌药物，特别是MM药物，需要大量的财政投入和漫长的开发过程。药物再利用的研究涉及探索现有药物用于新治疗用途的潜力。这可以显着减少时间和成本，而这通常是多发性骨髓瘤患者最关心的问题。考虑到其先前的临床前和临床开发，利用现有的非癌症药物进行各种骨髓瘤治疗是一种高效且具有成本效益的策略。这些药物在靶向与 MM 进展和耐药相关的关键途径方面显示出巨大的潜力。沙利度胺就是通过这一策略取得成功的例证。本综述深入探讨了当前的趋势、MM 传统疗法面临的挑战以及重新利用 MM 药物的重要性。这篇综述重点介绍了具有潜在显着抗骨髓瘤特性和抗肿瘤作用的传统疗法的不全面列表。此外，我们还提供有关资源的宝贵见解，有助于简化和加速 MM 领域的药物再利用工作。

MM is a common type of cancer that unfortunately leads to a significant number of deaths each year. The majority of the reported MM cases are detected in the advanced stages, posing significant challenges for treatment. Additionally, all MM patients eventually develop resistance or experience relapse; therefore, advances in treatment are needed. However, developing new anti-cancer drugs, especially for MM, requires significant financial investment and a lengthy development process. The study of drug repurposing involves exploring the potential of existing drugs for new therapeutic uses. This can significantly reduce both time and costs, which are typically a major concern for MM patients. The utilization of pre-existing non-cancer drugs for various myeloma treatments presents a highly efficient and cost-effective strategy, considering their prior preclinical and clinical development. The drugs have shown promising potential in targeting key pathways associated with MM progression and resistance. Thalidomide exemplifies the success that can be achieved through this strategy. This review delves into the current trends, the challenges faced by conventional therapies for MM, and the importance of repurposing drugs for MM. This review highlights a noncomprehensive list of conventional therapies that have potentially significant anti-myeloma properties and anti-neoplastic effects. Additionally, we offer valuable insights into the resources that can help streamline and accelerate drug repurposing efforts in the field of MM.